Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites

Objective: The objective of this study was to conduct feasibility study of phase III breast and lung cancer clinical trials in India. Materials and Methods: Study synopsis and feasibility questionnaire were mailed to 300 oncologists for each indication. Criteria of selection were enrolment of ≥2 pat...

Full description

Bibliographic Details
Main Authors: Varun M Mehta, Arun D Bhatt
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Perspectives in Clinical Research
Subjects:
Online Access:http://www.picronline.org/article.asp?issn=2229-3485;year=2013;volume=4;issue=4;spage=211;epage=214;aulast=Mehta
id doaj-ae28b25ae8a44984a9279d38d529e7e7
record_format Article
spelling doaj-ae28b25ae8a44984a9279d38d529e7e72020-11-24T23:57:10ZengWolters Kluwer Medknow PublicationsPerspectives in Clinical Research2229-34852013-01-014421121410.4103/2229-3485.120169Feasibility study of clinical trial for breast cancer and lung cancer at Indian sitesVarun M MehtaArun D BhattObjective: The objective of this study was to conduct feasibility study of phase III breast and lung cancer clinical trials in India. Materials and Methods: Study synopsis and feasibility questionnaire were mailed to 300 oncologists for each indication. Criteria of selection were enrolment of ≥2 patients per month, frequency of Ethics Committee (EC) meeting ≤4 weeks, dropout rate <20%, adequacy of infrastructure and training of site in good clinical practice (GCP). Descriptive analyses of the data were performed. Results: For both indications, 50/300 (16.7%) sites responded. The median number of patients seen by a site per month for breast and lung cancer was 20 (range 0-300) and 10 (range 0-75), respectively. Median number of eligible patients was 4 (range 0-20) and 3 (range 0-15) per month, for breast and lung cancer respectively. The frequency of EC meeting was ≤4 weeks at 36-56% of sites. All sites were trained in GCP and had adequate infrastructure to conduct the clinical trial. For breast cancer 22 (44%) sites (public 14 [28%]; private 8 [16%)]), and for lung cancer 18 (36%) sites (public 15 [30%], private: 3 [6%]) met the criteria of selection. Conclusion: Preliminary feasibility study would require for confirmation of the important feasibility criteria by in depth discussion during the personal visit to the potential sites.http://www.picronline.org/article.asp?issn=2229-3485;year=2013;volume=4;issue=4;spage=211;epage=214;aulast=MehtaBreast cancerfeasibility studylung cancer
collection DOAJ
language English
format Article
sources DOAJ
author Varun M Mehta
Arun D Bhatt
spellingShingle Varun M Mehta
Arun D Bhatt
Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites
Perspectives in Clinical Research
Breast cancer
feasibility study
lung cancer
author_facet Varun M Mehta
Arun D Bhatt
author_sort Varun M Mehta
title Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites
title_short Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites
title_full Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites
title_fullStr Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites
title_full_unstemmed Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites
title_sort feasibility study of clinical trial for breast cancer and lung cancer at indian sites
publisher Wolters Kluwer Medknow Publications
series Perspectives in Clinical Research
issn 2229-3485
publishDate 2013-01-01
description Objective: The objective of this study was to conduct feasibility study of phase III breast and lung cancer clinical trials in India. Materials and Methods: Study synopsis and feasibility questionnaire were mailed to 300 oncologists for each indication. Criteria of selection were enrolment of ≥2 patients per month, frequency of Ethics Committee (EC) meeting ≤4 weeks, dropout rate <20%, adequacy of infrastructure and training of site in good clinical practice (GCP). Descriptive analyses of the data were performed. Results: For both indications, 50/300 (16.7%) sites responded. The median number of patients seen by a site per month for breast and lung cancer was 20 (range 0-300) and 10 (range 0-75), respectively. Median number of eligible patients was 4 (range 0-20) and 3 (range 0-15) per month, for breast and lung cancer respectively. The frequency of EC meeting was ≤4 weeks at 36-56% of sites. All sites were trained in GCP and had adequate infrastructure to conduct the clinical trial. For breast cancer 22 (44%) sites (public 14 [28%]; private 8 [16%)]), and for lung cancer 18 (36%) sites (public 15 [30%], private: 3 [6%]) met the criteria of selection. Conclusion: Preliminary feasibility study would require for confirmation of the important feasibility criteria by in depth discussion during the personal visit to the potential sites.
topic Breast cancer
feasibility study
lung cancer
url http://www.picronline.org/article.asp?issn=2229-3485;year=2013;volume=4;issue=4;spage=211;epage=214;aulast=Mehta
work_keys_str_mv AT varunmmehta feasibilitystudyofclinicaltrialforbreastcancerandlungcanceratindiansites
AT arundbhatt feasibilitystudyofclinicaltrialforbreastcancerandlungcanceratindiansites
_version_ 1725455298414510080